SeekingAlpha · Sep 10, 2026
Roivant Sciences Ltd. (ROIV) Discusses Top Line Results from PHocus Study of Mosliciguat in PH-ILD - Slideshow
2026-09-10. The following slide deck was published by Roivant Sciences Ltd.
RO
NASDAQ · ROIV
Roivant Sciences Ltd.
Healthcare · Biotechnology
$39.50
Down-$1.52 (-3.71%)
Updated Sep 16, 2026, 9:32 AM
SID Score
7.5/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 14.83B
- P/E ratio
- -38.83
- Dividend yield
- 0.00%
- 52-week range
- $14.50 – $42.50
- Volume
- 8.1M
- Avg. volume
- 8.16M
Price performance
ROIV price history
1M range · 20 trading sessions · Daily adjusted prices
ROIV closed at $39.50 after 20 trading sessions, up 5.70% for the selected period.
- Last close
- $39.50
- Period change
- +5.70%
- Period low
- $34.18
- Period high
- $41.81
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $41.14 | $41.14 | $39.215 | $39.50 | 8.1M |
| Sep 14, 2026 | $40.64 | $41.60 | $40.44 | $41.02 | 7.59M |
| Sep 11, 2026 | $41.22 | $41.83 | $40.51 | $40.82 | 5.96M |
| Sep 10, 2026 | $41.265 | $41.405 | $40.215 | $40.94 | 6.54M |
| Sep 9, 2026 | $41.39 | $42.275 | $41.0808 | $41.81 | 11.15M |
| Sep 8, 2026 | $39.98 | $42.50 | $38.41 | $41.48 | 24.67M |
| Sep 4, 2026 | $34.20 | $35.145 | $33.88 | $34.93 | 5.24M |
| Sep 3, 2026 | $34.35 | $34.43 | $33.67 | $34.41 | 6.86M |
| Sep 2, 2026 | $34.64 | $35.0365 | $33.43 | $34.18 | 6.2M |
| Sep 1, 2026 | $34.64 | $34.95 | $34.26 | $34.52 | 6.91M |
| Aug 31, 2026 | $34.83 | $35.34 | $34.015 | $34.64 | 39.47M |
| Aug 28, 2026 | $37.01 | $37.13 | $34.685 | $34.71 | 8.76M |
| Aug 27, 2026 | $36.845 | $37.81 | $36.50 | $37.58 | 4.92M |
| Aug 26, 2026 | $36.925 | $36.93 | $36.32 | $36.75 | 5.26M |
| Aug 25, 2026 | $36.82 | $37.29 | $36.31 | $36.47 | 4.48M |
| Aug 24, 2026 | $36.22 | $36.569 | $35.705 | $36.36 | 5.12M |
| Aug 21, 2026 | $37.03 | $37.18 | $36.225 | $36.30 | 6.19M |
| Aug 20, 2026 | $36.91 | $37.55 | $36.68 | $36.84 | 3.13M |
| Aug 19, 2026 | $37.83 | $37.97 | $36.75 | $37.40 | 5.81M |
| Aug 18, 2026 | $35.91 | $37.46 | $35.86 | $37.37 | 6.41M |
Latest ROIV news
The latest Smart Investors Daily articles mentioning ROIV.
Stock researchCompany · Overview
ROIV research
Overview
Company profile and research snapshot.
Company profile
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $23.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | TD Cowen | Buy | — |
| Sep 9, 2026 | Guggenheim | Buy | — |
| Sep 8, 2026 | Jefferies | Buy | — |
| Sep 8, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 28, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Sep 10, 2026
Roivant Sciences Ltd. (ROIV) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Yahoo · Sep 10, 2026
Podcast: key readouts from ESC and ERS
The healthcare team dive into the latest data and emerging trends from the ESC Congress and ERS Congress.
SeekingAlpha · Sep 9, 2026
Roivant Sciences Ltd. (ROIV) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Roivant Sciences Ltd. (ROIV) 12th Annual Cantor Fitzgerald Global Healthcare Conference September 9, 2026 1:00 PM EDTCompany ParticipantsMatthew Gline - CEO...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
